KR20240073114A - Shp-2 억제제와 kras g12d 억제제의 병용 요법 - Google Patents

Shp-2 억제제와 kras g12d 억제제의 병용 요법 Download PDF

Info

Publication number
KR20240073114A
KR20240073114A KR1020247015004A KR20247015004A KR20240073114A KR 20240073114 A KR20240073114 A KR 20240073114A KR 1020247015004 A KR1020247015004 A KR 1020247015004A KR 20247015004 A KR20247015004 A KR 20247015004A KR 20240073114 A KR20240073114 A KR 20240073114A
Authority
KR
South Korea
Prior art keywords
inhibitor
shp
alkyl
kras
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247015004A
Other languages
English (en)
Korean (ko)
Inventor
질 할린
제임스 게일 크리스텐슨
빅키 보우컷
피터 올슨
Original Assignee
미라티 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미라티 테라퓨틱스, 인크. filed Critical 미라티 테라퓨틱스, 인크.
Publication of KR20240073114A publication Critical patent/KR20240073114A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247015004A 2021-10-05 2022-10-04 Shp-2 억제제와 kras g12d 억제제의 병용 요법 Pending KR20240073114A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252561P 2021-10-05 2021-10-05
US63/252,561 2021-10-05
PCT/US2022/045623 WO2023059598A1 (en) 2021-10-05 2022-10-04 Combination therapies of kras g12d inhibitors with shp-2 inhibitors

Publications (1)

Publication Number Publication Date
KR20240073114A true KR20240073114A (ko) 2024-05-24

Family

ID=85803689

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015004A Pending KR20240073114A (ko) 2021-10-05 2022-10-04 Shp-2 억제제와 kras g12d 억제제의 병용 요법

Country Status (6)

Country Link
US (1) US20240423984A1 (https=)
EP (1) EP4412719A4 (https=)
JP (1) JP2024540839A (https=)
KR (1) KR20240073114A (https=)
CN (1) CN118401254A (https=)
WO (1) WO2023059598A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4436571A4 (en) * 2021-11-24 2025-10-15 Merck Sharp & Dohme Llc SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
EP4531846A1 (en) * 2022-06-03 2025-04-09 Verastem, Inc. Combination therapy for treating abnormal cell growth
JP2025523101A (ja) * 2022-07-12 2025-07-17 メッドシャイン ディスカバリー インコーポレイテッド ピペラジン架橋置換複素環ピリミジン系化合物
CN121909197A (zh) * 2023-08-22 2026-04-21 赛诺菲 2-(3,8-二氮杂双环[3.2.1]辛-3-基)-1,3,5-三嗪衍生物作为用于治疗癌症的kras g12d抑制剂
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2026080796A1 (en) * 2024-10-11 2026-04-16 Mirati Therapeutics, Inc. Mrtx1133 capsule pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4225383A4 (en) 2020-10-08 2024-12-11 Kumquat Biosciences Inc. MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES
US20240166669A1 (en) * 2021-03-05 2024-05-23 Nikang Therapeutics, Inc. Quinazoline amine derivatives as kras inhibitors
TW202317589A (zh) * 2021-07-14 2023-05-01 美商尼坎醫療公司 作為ｋｒａｓ抑制劑的伸烷基衍生物

Also Published As

Publication number Publication date
CN118401254A (zh) 2024-07-26
EP4412719A1 (en) 2024-08-14
US20240423984A1 (en) 2024-12-26
WO2023059598A1 (en) 2023-04-13
JP2024540839A (ja) 2024-11-06
EP4412719A4 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
KR20240089358A (ko) Sos1 억제제와 kras g12d 억제제의 병용 요법
KR20240073114A (ko) Shp-2 억제제와 kras g12d 억제제의 병용 요법
KR20210113587A (ko) 병용 요법
JP7546549B2 (ja) 組み合わせ療法
JP2025000632A (ja) 組み合わせ療法
JP2025000630A (ja) 組み合わせ療法
EP3849537B1 (en) Combination therapies
KR20240089340A (ko) 범 ErbB 계열 억제제와 KRAS G12D 억제제의 병용 요법
EP4284370A1 (en) Combination therapies
HK40109896A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
KR20250070104A (ko) 조합 요법
HK40109895A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
EA044829B1 (ru) Способы комбинированной терапии
HK40059386A (zh) 组合疗法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000